This study assess the pharmacokinetics of vildagliptin in mild, moderate and severe renal impaired patients
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
96
Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
Matching healthy volunteers receiving 25 mg vildagliptin once daily.
Novartis Investigator Site
Moscow, Russia
Measure: pharmacokinetics of vildagliptin and its metabolites
Time frame: 14 days
Measure: safety assessments will include vital signs, electrocardiograms and adverse events
Time frame: 14 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Matching healthy volunteers receiving 50 mg vildagliptin once daily